N-Acetylcysteine: A potential therapeutic agent for SARS-CoV-2

Area of Science:

• Immunology
• Biochemistry
• Infectious Diseases

Background:

• COVID-19 severity is linked to T cell exhaustion, high viral load, and elevated inflammatory cytokines (TNF-ɑ, IL1β, IL6, IL10).
• Oxidative stress and impaired cellular redox status contribute to inflammation and poor immune response in SARS-CoV-2 infection.
• N-acetylcysteine (NAC) is known to improve redox status, replenish glutathione, and modulate inflammatory pathways.

Purpose of the Study:

• To explore the potential therapeutic mechanisms of N-acetylcysteine (NAC) in treating COVID-19.
• To present evidence supporting NAC's role in mitigating SARS-CoV-2-induced disease severity.

Main Methods:

• Review of in vivo, in vitro, and human clinical trial data on N-acetylcysteine (NAC).
• Analysis of NAC's effects on glutathione synthesis, T cell proliferation, and inflammatory pathways (NLRP3 inflammasome, TNF-ɑ).
• Evaluation of NAC's potential to counteract oxidative stress and viral load in COVID-19.

Main Results:

• NAC enhances glutathione stores and T cell proliferative responses in human trials.
• NAC inhibits the NLRP3 inflammasome pathway in vitro and reduces plasma TNF-ɑ in clinical studies.
• NAC's antioxidant properties may reduce viral load and mitigate oxidative stress-induced cell death.

Conclusions:

• N-acetylcysteine (NAC) shows promise as a therapeutic agent for COVID-19.
• NAC may improve COVID-19 outcomes by increasing glutathione, enhancing T cell immunity, and modulating inflammation.
• Further investigation into NAC's efficacy for COVID-19 treatment is warranted.